40 completed, 11 terminated, 11 unknown, 3 recruiting. 70 Phase 2, 3 Phase 1, 3 Phase 3.
Follow Donepezil: new trials by email Literature Review of Donepezil trials Research Report on Donepezil
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open Trial of a Novel Pharmacotherapy for Habit Modification in Anorexia Nervosa Donepezil - Anorexia Nervosa | Phase 2 | Not yet recruiting | New York State Psychiatric Institute | 10 | 2027-01-01 | 2026-10-23 |
| Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type Huperzine A Controlled-Release Tablets, Donepezil hydrochloride tablets, Huperzine A controlled-release tablets placebo; Donepezil hydrochloride tablets placebo - Alzheimer Dementia | Phase 2 / Phase 3 | Recruiting | Wanbangde Pharmaceutical Group Co., LTD | 720 | 2025-08-29 | 2026-08-17 |
| Effect of Acetylcholinesterase Inhibitors on Bone Metabolism Donepezil, Memantine - Osteoporosis | Phase 2 | Recruiting | Duke University | 45 | 2025-02-03 | 2026-09-21 |
| Acetylcholinesterase Inhibitor in Anorexia Nervosa: Multicenter, Double-Blind, Placebo-Controlled Trial Donepezil 2.5 mg, Donepezil 5 mg, Placebo Comparator - Anorexia Nervosa Restricting Type | Phase 2 | Not yet recruiting | Centre Hospitalier St Anne | 147 | 2024-11-01 | 2024-11-14 |
| Investigating the Cholinergic Contribution to Gait Dysfunction in Parkinson's Disease Donepezil (Aricept) - Parkinson Disease | Phase 2 | Completed | University of Virginia | 6 | 2024-11-01 | 2026-03-09 |
| Randomized Clinical Trial of Donepezil for the Treatment of Mild Cognitive Impairment in Parkinson's Disease Donepezil Hydrochloride, Placebo - Parkinson Disease, Mild Cognitive Impairment | Phase 2 | Unknown | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 120 | 2023-10-01 | 2023-09-28 |
| A Clinical Trial to Access Pharmacokinetic Profiles and Safety of IVL3003. Aricept Tablet, IVL3003 - Alzheimer Disease | Phase 1 / Phase 2 | Active not recruiting | Inventage Lab., Inc. | 62 | 2023-04-01 | 2024-12-19 |
| Donepezil and Cognitive Training for Alcohol Use Disorder (AUD) Donepezil + Cognitive remediation therapy (CRT), Donepezil + Placebo CRT, Placebo medication + Cognitive remediation therapy (CRT) - Alcohol Use Disorder | Phase 2 | Recruiting | VA Connecticut Healthcare System | 160 | 2022-08-08 | 2026-06-23 |
| Donepezil for Oxaliplatin-induced Neuropathy Peripheral Neuropathy: Proof of Concept Study DONEPEZIL, PLACEBO - Digestive Oncology, Supportive Care | Phase 2 | Completed | University Hospital, Clermont-Ferrand | 77 | 2022-06-02 | 2024-04-05 |
| Efficacy of Chinese Traditional Medicine "Smart Soup" in Cognition and Behavior Regulation in Alzheimer's Disease smart soup, Donepezil, Memantine - Alzheimer Disease, Mild Cognitive Impairment | Phase 2 | Unknown | Peking Union Medical College Hospital | 180 | 2022-06-01 | 2022-09-14 |
| A Phase 2 Clinical Study to Explore the Optimal Dosage/Administration of PM012 Tablet in Alzheimer's Disease PM012, PM012 Placebo, Donepezil - Mild Alzheimer Disease | Phase 2 / Phase 3 | Unknown | Mediforum Ltd., Co. | 312 | 2020-11-27 | 2023-04-18 |
| The Effect of Donepezil on Wound Healing Donepezil, Placebo oral tablet, Topical Zinc Oxide - Wound Heal | Phase 2 | Unknown | University of Maryland, Baltimore | 20 | 2020-08-30 | 2023-05-22 |
| The Effect of Donepezil on Glycemic Control in Type II Diabetics Donepezil 5-10 Mg Oral Tablet, Placebo Oral Tablet - Diabetes Mellitus, Type 2 | Phase 2 | Terminated | University of Maryland, Baltimore | 7 | 2019-07-12 | 2023-10-13 |
| The Effect of Donepezil in Radiotherapy-related Cognitive Impairment. Donepezil Hydrochloride, Placebo - Radiation Injuries, Cognitive Impairment | Phase 2 | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 238 | 2019-05-01 | 2019-11-25 |
| Effect of Electroacupuncture Combined With Donepezil for Treating Alzheimer's Disease acupuncture, donepezil - Cognitive Impairment | Phase 2 | Unknown | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | 334 | 2017-06-01 | 2017-05-16 |
| Study of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil(DRAMA) Donepezil, DHP1401, Placebo - Mild-moderate Alzheimer's Disease | Phase 2 | Completed | Daehwa Pharmaceutical Co., Ltd. | 180 | 2016-12-28 | 2019-08-20 |
| A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson Patients Duloxetine, Donepezil, Modafinil - Parkinson's Disease | Phase 2 | Withdrawn | University of Chicago | 2016-11-01 | 2017-12-12 | |
| Clinical Efficacy of Ginkgo Biloba Extract in the Treatment of Alzheimer's Disease Ginkgo biloba dispersible tablets, Donepezil, Ginkgo biloba dispersible tablets and Donepezil - Alzheimer's | Phase 2 / Phase 3 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 240 | 2016-08-10 | 2019-08-07 |
| Study of STA-1 as an Add-on Treatment to Donepezil Donepezil,, STA-1, placebo - Alzheimer Disease | Phase 2 | Unknown | Sinphar Pharmaceutical Co., Ltd | 136 | 2015-12-01 | 2014-08-20 |
| A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type Donepezil, Solifenacin - Dementia of Alzheimer's Type | Phase 2 | Completed | Chase Pharmaceuticals Corporation, an affiliate of Allergan plc | 28 | 2015-10-07 | 2019-03-05 |
Showing 20 of 70. Sign in to see all of them.
Alzheimer Disease (31) · Cognitive Dysfunction (7) · Dementia (7) · Parkinson Disease (6) · Autism Spectrum Disorder (3) · Autistic Disorder (3) · Cognition Disorders (3) · Anorexia Nervosa (2) · Brain Diseases (2) · Central Nervous System Diseases (2) · Delirium (2) · Down Syndrome (2) · Feeding and Eating Disorders (2) · Habits (2) · Lewy Body Disease (2)
AbbVie (prior sponsor, Abbott) (4) · Eisai Inc. (4) · GlaxoSmithKline (3) · AstraZeneca (2) · Eisai Co., Ltd. (2) · Eisai Limited (2) · National Center for Research Resources (NCRR) (2) · National Institute of Mental Health (NIMH) (2) · Sanofi (2) · University of Maryland, Baltimore (2) · Wake Forest University Health Sciences (2) · Abramson Cancer Center at Penn Medicine (1) · Beth Israel Deaconess Medical Center (1) · Birte Glenthoj (1) · Boehringer Ingelheim (1)
United States (37) · United Kingdom (9) · Russia (8) · Germany (7) · South Korea (7) · Australia (6) · Canada (6) · Czechia (6) · France (6) · Poland (6) · South Africa (6) · Spain (6) · China (5) · Ukraine (5) · Bulgaria (4)
Itaru Arimoto (2) · Laura Gault, MD (2) · Allan L Reiss (1) · Andrew Strasser, MBBS, PhD (1) · Ashura W Buckley, M.D. (1) · Benjamin L. Handen, PhD (1) · Bertrand Gaymard, MD, PhD (1) · Birte Glenthoj, MD, DMSc. (1)
PMID 29854923, PMID 16549835, PMID 18296124, PMID 19836169, PMID 20872778, PMID 21295494, PMID 21679156, PMID 22091574, PMID 24418055, PMID 26697847, PMID 27662321, PMID 27756421, PMID 28550255, PMID 28673322, PMID 29854928, PMID 30755255, PMID 33189083, PMID 35662833, PMID 35799138, PMID 35908254, PMID 36168659, PMID 37267443, PMID 39111388, PMID 39566720
2009 (3), U10CA081851 (2), 2004 (1), R01AA029075 (1), R21AG027549 (1), R21AG078982 (1), R21DA029787 (1), R21MH064941 (1), R34MH085899 (1), R56AG021476 (1)